1 / 30

Epidemiology of Tuberculosis

Epidemiology of Tuberculosis. Prof. Ashry Gad Mohamed MBChB, MPH, DrPH. Objectives. 1. To perceive the magnitude of global tuberculosis problem. 2. To understand the cycle of infection of tuberculosis. 3. To understand methods of prevention and control of tuberculosis.

rtillotson
Télécharger la présentation

Epidemiology of Tuberculosis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Epidemiology of Tuberculosis Prof. Ashry Gad Mohamed MBChB, MPH, DrPH

  2. Objectives 1. To perceive the magnitude of global tuberculosis problem. 2. To understand the cycle of infection of tuberculosis. 3. To understand methods of prevention and control of tuberculosis.

  3. Magnitude of the problem • Globally, 9.2 million new cases • 1.7 million deaths from TB, 2006 • of which 0.7 million cases and 0.2 million deaths were in HIV-positive people. • 95% from developing countries • 19-43% of world population is infected • Between 2000-2020 G. One billion will get infection 200 million get sick 35 million will die

  4. Tuberculosis (TB) remains one of the world’s deadliest communicable diseases. In 2013, an estimated 9.0 million people developed TB and 1.5 million died from the disease, 360 000 of whom were HIV-positive. TB is present in all regions of the world

  5. Of the estimated 9 million people who developed TB in 2013, more than half (56%) were in the South-East Asia and Western Pacific Regions. A further one quarter were in the African Region, which also had the highest rates of cases and deaths relative to population. India and China alone accounted for 24% and 11% of total cases, respectively.

  6. TB is slowly declining each year and it is estimated that 37 million lives were saved between 2000 and 2013 through effective diagnosis and treatment. About 60% of TB cases and deaths occur among men

  7. Almost 60 per cent of TB cases worldwide are now detected, and out of those, the vast majority are cured. Over the past decade, 26 million patients have been placed on effective TB treatment thanks to the efforts of governments and a wide range of partners. But the disease still kills 4400 people every day."

  8. TB in Saudi Arabia • During the period 2000-2013 there were a total of 64,345 reported TB cases. Of these 48% were Non-Saudis. • TB annual incidence rate ranged between 14 and 17/100,000. For Saudis, the rate ranged between 8.6 and 12.2/100,000.

  9. Non-Saudis had 2-3 times higher incidence. Disease trend was rising over the first 10 years(2000-2010) then it started to fall slightly. • The incidence increased with age, but only people older than 45 years showed a declining trend. • Regional variations were observed. Makkah and Jazan regions had the highest incidence rates. Disease trends were rising over the last 10 years in Makkah and Central regions.

  10. Factors contributing to rise of TB occurrence • HIV/AIDS 15% of deaths among AIDS patients due to TB. • Poorly managed TB programs Wrong treatment regimen and inconsistent or partial treatment lead to multidrug resistant TB (MDR-TB). • Movement of people Global trade, traveling and migration

  11. Agent Mycobacterium tuberculosis complex • M. Tuberculosis • M. bovis • M. africanum • M. microti • M. canetti

  12. Tuberculosis Bacillus • Bacillus is thin, somewhat curved, from 1 to 4 microns in length, with a complex cellular wall (lipid core) responsible for its characteristic coloration (acid-alcohol-resistant). • Susceptible to sunlight, heat and dryness. • Strictly parasitic and airborne; slow multiplier.

  13. Reservoir • Human • Cattle

  14. Modes of transmission • 1-Air-borne droplet nuclei 1-5 μ m in diameter. remain airborne for long times. • Factors determining the probability of infection No. of organisms expelled Conc. of organisms in air Length of exposure Immune status of exposed person

  15. 2-Ingesion of raw milk & diary products. • 3-Direct invasion through wounds

  16. Immune System Response • Bacteria invades lung tissue • White cells surround the invaders and try to destroy them. • Body builds a wall of cells and fibers around the bacteria to confine them, forming a small hard lump.

  17. Bacteria cannot cause more damage as long as the confining walls remain unbroken. • Most infected individuals never progress to active TB. • Most remain latently-infected for life. • Infection progresses and develops into active TB in less than 10% of the cases.

  18. Incubation period: 4-12 weeks.

  19. Diagnosis: No single test is diagnostic in all situations, but complementary techniques should be used to generate complete & rapid information. • 1-tuberculin test to identify infection* • 2-Acid fast bacilli smear • 3-Culture • MMR & X-ray • Genotype (DNA fingerprinting)*

  20. Tuberculin test 0.1ml intradermal. • 48-72 hours • false negative poor nutrition poor general health overwhelming acute illness Immunosuppression • False positive BCG vaccination Other mycobacteria infection

  21. Interpretation: • On the basis of sensitivity, specificity and the prevalence of TB in different groups three cut points have been recommended for defining positive tuberculin reaction. • 5mm. 10 mm. 15 mm.

  22. Classification of tuberculosis Based on exposure history, infection & disease. • Class 0: No history of exposure Negative tuberculin test (no infection) • Class 1: History of exposure Negative tuberculin

  23. Class 2: Positive tuberculin (latent infection) Negative X-ray Negative bacteriology & radiol. • Class 3: Patients with clinically active TB Whose diagnostic procedures were completed (positive clinical, bacteriological or/and radiological of current TB).

  24. Remain in this stage until treatment is completed • Pulmonary • Pleural • Lymphatic • Bone and/or joint • Genitourinary • Miliary • Meningeal • Peritonial • Others

  25. Class 4: -Not clinically active TB -Receiving treatment for latent infection -Completed previously prescribed -course of chemotherapy -Abnormal stable radiol. With negative bacteriology and positive tuberculin

  26. Class 5: Tuberculosis suspect -Clinically active disease has not been ruled out. -Persons not adequately treated in the past. -Patient should not remain in this stage more than 3 months

  27. Prevention and control Prevention: • Case finding • Vaccination • Chemoprophylasis • Environmental

  28. Control: • Reporting • Isolation • Concurrent disinfect ion • Contact measures • Treatment

  29. Elements of the DOTS Strategy • Political commitment • Bacteriological diagnostic capacity • Regular supply ofmedications and supplies • Directly Observed Treatment Strategy • Information system Registries

  30. Two potential barriers The first is multidrug-resistant tuberculosis (MDR-TB), Given limited laboratory and treatment capacity, countries project they will provide treatment only to an estimated 10% of people with MDR-TB worldwide in 2008. The second threat to continued progress is the lethal combination of TB and HIV, particularly in Africa

More Related